AbbVie (NYSE: ABBV) and Immunome have announced a collaboration to discover up to 10 novel antibody-target pairs for the treatment of three specific tumor types using Immunome's Discovery Engine. 
As part of the agreement, Immunome will grant AbbVie the option to purchase worldwide rights for the target-antibody pairs, and will receive an upfront payment of $30 million and potentially up to $70 million in platform access payments.
Immunome is also eligible for development and first commercial sale milestones of up to $120 million per target for certain products derived from the target-antibody pairs that AbbVie elects to purchase, as well as tiered royalties on global sales.
This collaboration expands AbbVie's oncology pipeline and allows Immunome to leverage AbbVie's development and commercialization expertise to bring new therapies to patients with life-threatening cancers.
See full press release here
Rate this article